ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
USP10 Inhibits Ferroptosis via Deubiquinating POLR2A in Head and Neck Squamous Cell Carcinoma.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- OTUD5 promotes AML progression by stabilizing SLC7A11 to suppress ferroptosis.Cell cycle (Georgetown, Tex.) · 2026Article
- USP10 deubiquitinase: Physiological function, diseases and therapeutic target (Review).International journal of molecular medicine · 2026Review
- Article
- LMO7-mediated POLR2A degradation promotes cellular senescence through the MDM4/p53/p21 axis.Cell death & disease · 2026Article
- Review
- CDCSI: a machine learning-based interpretable cell death and cellular senescence index for prognosis improvement, immune landscape characterization, and therapeutic response prediction in head and neck squamous cell carcinoma.Frontiers in immunology · 2026Article
- USP10 Inhibits Ferroptosis via Deubiquinating POLR2A in Head and Neck Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Ferroptosis has become a new way to induce cell death in cancer therapy. Deubiquitinating enzymes (DUBs) contribute to cancer ferroptosis, but underlying mechanisms are not completely understood. Here, it is discovered that USP10 as a member of DUBs, is tightly associated with a poor prognosis in patients with head and neck squamous cell carcinoma (HNSCC). Functionally, USP10 inhibits ferroptosis via transcriptionally upregulating the expression of SLC7A11 in HNSCC. Targeting USP10 via gene depletion and antagonist sensitizes HNSCC cells to ferroptosis inducers both in vitro and in vivo. Mechanistically, USP10 directly interacts with the largest RNA Polymerase II Subunit A (POLR2A), removes the K48- and K63-linked ubiquitin chains of POLR2A through its deubiquitinase activity and prevents ubiquitin-mediated degradation. Then, POLR2A transcriptionally activates SLC7A11, eventually leading to the suppression of ferroptosis. Overall, the study indicates that a novel USP10-POLR2A-SLC7A11 axis regulates ferroptosis, positioning USP10 as a potential therapeutic target in patients with HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.